193 related articles for article (PubMed ID: 35628360)
1. Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease.
Wang M; Li J; Li H; Dong B; Jiang J; Liu N; Tan J; Wang X; Lei L; Li H; Sun H; Tang M; Wang H; Yan H; Li Y; Jiang J; Peng Z
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628360
[TBL] [Abstract][Full Text] [Related]
2. Impaired Hepatic Vitamin A Metabolism in NAFLD Mice Leading to Vitamin A Accumulation in Hepatocytes.
Saeed A; Bartuzi P; Heegsma J; Dekker D; Kloosterhuis N; de Bruin A; Jonker JW; van de Sluis B; Faber KN
Cell Mol Gastroenterol Hepatol; 2021; 11(1):309-325.e3. PubMed ID: 32698042
[TBL] [Abstract][Full Text] [Related]
3. 17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.
Ma Y; Brown PM; Lin DD; Ma J; Feng D; Belyaeva OV; Podszun MC; Roszik J; Allen JN; Umarova R; Kleiner DE; Kedishvili NY; Gavrilova O; Gao B; Rotman Y
Hepatology; 2021 May; 73(5):1701-1716. PubMed ID: 32779242
[TBL] [Abstract][Full Text] [Related]
4. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.
Arndt S; Wacker E; Dorn C; Koch A; Saugspier M; Thasler WE; Hartmann A; Bosserhoff AK; Hellerbrand C
Gut; 2015 Jun; 64(6):973-81. PubMed ID: 25011936
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of
Luukkonen PK; Sakuma I; Gaspar RC; Mooring M; Nasiri A; Kahn M; Zhang XM; Zhang D; Sammalkorpi H; Penttilä AK; Orho-Melander M; Arola J; Juuti A; Zhang X; Yimlamai D; Yki-Järvinen H; Petersen KF; Shulman GI
Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2217543120. PubMed ID: 36669104
[TBL] [Abstract][Full Text] [Related]
7. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of
Di Sessa A; Umano GR; Cirillo G; Passaro AP; Verde V; Cozzolino D; Guarino S; Marzuillo P; Miraglia Del Giudice E
World J Gastroenterol; 2020 Sep; 26(36):5474-5483. PubMed ID: 33024398
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
Bozic M; Guzmán C; Benet M; Sánchez-Campos S; García-Monzón C; Gari E; Gatius S; Valdivielso JM; Jover R
J Hepatol; 2016 Oct; 65(4):748-757. PubMed ID: 27245430
[TBL] [Abstract][Full Text] [Related]
9. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
[TBL] [Abstract][Full Text] [Related]
10. A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet.
Alshawsh MA; Alsalahi A; Alshehade SA; Saghir SAM; Ahmeda AF; Al Zarzour RH; Mahmoud AM
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164140
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
13. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte-Stellate Cell Crosstalk.
Jiang L; Yang M; Li X; Wang Y; Zhou G; Zhao J
J Clin Endocrinol Metab; 2018 Nov; 103(11):3974-3985. PubMed ID: 30053055
[TBL] [Abstract][Full Text] [Related]
14. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
[TBL] [Abstract][Full Text] [Related]
15. Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Petta S; Valenti L; Svegliati-Baroni G; Ruscica M; Pipitone RM; Dongiovanni P; Rychlicki C; Ferri N; Cammà C; Fracanzani AL; Pierantonelli I; Di Marco V; Meroni M; Giordano D; Grimaudo S; Maggioni M; Cabibi D; Fargion S; Craxì A
J Clin Endocrinol Metab; 2017 Aug; 102(8):2660-2669. PubMed ID: 28472477
[TBL] [Abstract][Full Text] [Related]
16. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD.
Amangurbanova M; Huang DQ; Loomba R
Aliment Pharmacol Ther; 2023 Jan; 57(1):37-51. PubMed ID: 36349732
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
18. Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro.
Mahli A; Seitz T; Beckröge T; Freese K; Thasler WE; Benkert M; Dietrich P; Weiskirchen R; Bosserhoff A; Hellerbrand C
Cells; 2019 May; 8(5):. PubMed ID: 31096638
[TBL] [Abstract][Full Text] [Related]
19. Expression of Vsig4 attenuates macrophage-mediated hepatic inflammation and fibrosis in high fat diet (HFD)-induced mice.
Li Y; Sun JP; Wang J; Lu WH; Xie LY; Lv J; Li HX; Yang SF
Biochem Biophys Res Commun; 2019 Aug; 516(3):858-865. PubMed ID: 31266632
[TBL] [Abstract][Full Text] [Related]
20. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
